Related Experiment Video
Updated: Jul 12, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 16, 2010
Big endothelin analogues with inhibitory activity on endothelin-converting enzyme-1
1Third Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Abstract:
Big endothelin-1 (big ET-1) is converted into an active form, ET-1, by endothelin-converting enzyme-1 (ECE-1). To assess the mechanism of substrate recognition by ECE-1, we examined the effects of variously substituted analogues of big ET-1 on ECE-1 activity, using solubilized membranes prepared from human ECE-1-expressed CHO-K1 cells. Among the big ET-1 analogues tested, [21Phe]big ET-1[18-34] and [31Ala]big ET-1[18-34] exhibited significant inhibition of ECE-1. A kinetic analysis revealed [21Phe]big ET-1[18-34] to be a competitive inhibitor (Ki = 21 microM) and [31Ala]big ET-1[18-34] to be a noncompetitive inhibitor (Ki = 36 microM). These results suggested that ECE-1 recognizes big ET-1 at the P1 position and the C-terminal region in a different manner and that modification of these regions can produce ECE-1 inhibitors.
More Related Videos
Related Concept Videos
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

